Company: VRCA
Filing Date: 2025-12-23
Form Type: 424B3
Source: 0001193125-25-330986
Chunk: 14

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-23
Form: 424B3
Chunk 14
---
 Warrants issued to Kalehua in the Private Placement. Kalehua Capital Management LLC 
 (“Kalehua Management”) is the general partner and investment manager of Kalehua. Tai-Li Chang is the managing member of Kalehua Management and has voting and investment authority over all of the                                        
 shares beneficially owned by each of Kalehua and Kalehua Management. The address of Kalehua is 3819 Maple Avenue, Dallas, Texas 75219.                                                                                                    |

| (16) | “Beneficial Ownership Prior to this Offering” consists of (a) 47,155 shares of our common stock                                                                                                                                             
 issued to Parallax Biomedical Fund LP (“Parallax”) in the Private Placement and (b) 11,788 shares of our common stock issuable upon exercise of Common Warrants issued to Parallax in the Private Placement. The address of Parallax is c/o 
 Vista Point Capital, P.O. Box 357, Walnut Creek, California 94597.                                                                                                                                                                          |

Relationship with Selling Stockholders Each of the selling stockholders has not had any material relationship with the registrant or any of its predecessors or affiliates, within the past three years, except as described below. As discussed in greater detail above under the section titled “Prospectus Summary—Private Placement,” in November 2025, we entered into the Purchase Agreements with the selling stockholders, pursuant to which we sold and issued shares of our common stock, Pre-FundedWarrants and Common Warrants to purchase our common stock. The Purchase Agreements include certain registration rights, pursuant to which we agreed to prepare and file, within 30 days of closing, one or more registration statements with the SEC to register for resale the Resale Shares. As described below, the selling stockholders include several of our officers and directors, or affiliates thereof, and 5% or greater stockholders. Paul B. Manning is a beneficial owner of more than 5% of our common stock and has served as chairman of our board of directors since 2017. Jayson Rieger has served as our President and Chief Executive Officer and as a director since November 2024. 10

David Zawitz has served as our Chief Operating Officer since December 2024.

John Kirby has served as our Interim Chief Financial Officer since November 2024.

Noah Rosenberg has served as our Chief Medical Officer since March 2025.

Caligan Partners LP is, and prior to the Private Placement was, a beneficial owner of more than 5% of